menu
    • menu
    [{"orgOrder":0,"company":"Future Pak","sponsor":"Theratechnologies","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody, Unconjugated","year":"2025","type":"Acquisition","leadProduct":"Ibalizumab","moa":"T-cell surface antigen CD4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Future Pak","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Future Pak \/ Future Pak","highestDevelopmentStatusID":"15","companyTruncated":"Future Pak \/ Future Pak"},{"orgOrder":0,"company":"Future Pak","sponsor":"Jaguar Health","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2026","type":"Licensing Agreement","leadProduct":"Crofelemer","moa":"Cystic fibrosis transmembrane conductance regulator | Anoctamin-1","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Future Pak","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0.040000000000000001,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Future Pak \/ Future Pak","highestDevelopmentStatusID":"15","companyTruncated":"Future Pak \/ Future Pak"}]

    Find Clinical Drug Pipeline Developments & Deals by Future Pak

    Menu

    Future Pak

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Future Pak

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            Future Pak

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Crofelemer

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved FDF

                            Recipient : Jaguar Health

                            Deal Size : $38.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Jaguar Health Signs $38M U.S. License Deal with Future Pak for Crofelemer

                            Details : Through the licensing deal for Crofelemer, the agreement aims to address noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy.

                            Product Name : Mytesi

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : $18.0 million

                            January 12, 2026

                            Lead Product(s) : Crofelemer

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved FDF

                            Recipient : Jaguar Health

                            Deal Size : $38.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Future Pak

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            Future Pak

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ibalizumab

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Recipient : Theratechnologies

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Theratechnologies Announces Completion of Acquisition by Future Pak

                            Details : Trogarzo (ibalizumab) is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors.

                            Product Name : Trogarzo

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            September 25, 2025

                            Lead Product(s) : Ibalizumab

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Recipient : Theratechnologies

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            • Privacy policy
                            • Terms and conditions
                            • Disclaimers
                            • LinkedIn
                            • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.